Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Conditions:   Stage I Prostate Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8 Interventions:   Radiation: Hypofractionated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

For patients with oligometastatic prostate cancer there is an emerging data suggesting benefit of localized treatment of metastases with stereotactic body radiation therapy (SBRT) as an addition to systemic therapy. Bone metastases are the most common site of oligometastatic disease thus targeting the bone niche may help prevent spread of oligometastatic and micrometastatic disease. Radium 223 dichloride acts as a calcium mimetic targeting active areas of bone turnover observed in osteoblastic lesions.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Publish Only Source Type: research
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Lung cancer patients undergoing radiotherapy during the time of a declared...Read more on AuntMinnie.comRelated Reading: Single-dose brachytherapy treats low-risk prostate cancer ASTRO: Prior authorization delays radiation treatment SABR plus surgery is effective for treating lung cancer Shorter radiotherapy works for prostate cancer treatment ASTRO updates guideline for lung cancer radiation therapy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
In this study we evaluate the lesion detection efficacy of18F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a function of their PSA value.MethodsA total of 248 consecutive patients were evaluated and underwent scanning with18F-DCFPyL PET/CT for BCR between November 2016 and 2018 in two hospitals in the Netherlands. Patients were examined after radical prostatectomy (52%), external-beam radiation therapy (42%) or brachytherapy (6%). Imaging was performed 120  min after injection of a median dose of 311 MBq18F-DCFPyL.ResultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion sug...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
This study aims to investigate factors which correlate with development of fatigue.MethodsTwenty ‐seven men with high‐risk prostate cancer undergoing radiation therapy and 18 months of ADT were assessed for fatigue, haemoglobin (Hb), testosterone, magnetic resonance imaging (MRI) fat fraction (FF) and apparent diffusion coefficient (ADC), at baseline and at intervals after radiotherapy. Ch anges from baseline were analysed using pairedt‐tests. Linear time trends were assessed using linear mixed effect models.ResultsOverall, mean fatigue score increased from baseline to the 18 ‐month time interval (difference 4...
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Radiation Oncology —Original Article Source Type: research
CONCLUSIONS: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent. PMID: 31296421 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
We describe the incidental detection of a radiation-induced undifferentiated soft-tissue sarcoma with increased uptake on Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in a prostate cancer patient previously treated with surgery and external-beam radiotherapy. Results were confirmed by histological analysis. Ga-PSMA is known to bind not only to PSMA-expressing prostate cancer cells but also to the neovasculature of various other solid tumors. A careful Ga-PSMA PET/CT review of previously irradiated areas is warranted so as not to miss radiation-induced sarcoma in prostate cancer patients. PMID: 31274636 ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Nucl Med Source Type: research
We describe the incidental detection of a radiation-induced undifferentiated soft-tissue sarcoma with increased uptake on 68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in a prostate cancer patient previously treated with surgery and external-beam radiotherapy. Results were confirmed by histological analysis. 68Ga-PSMA is known to bind not only to PSMA-expressing prostate cancer cells but also to the neovasculature of various other solid tumors. A careful 68Ga-PSMA PET/CT review of previously irradiated areas is warranted so as not to miss radiation-induced sarcoma in prostate cancer patients.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
CONCLUSIONS: Our results also demonstrate long-term overall survival benefits for EBRT + BT ± ADT, and greater bowel and bladder side effects over a decade, compared to RP. The RP group had advantage for long-term prostate-cancer specific mortality, compared to EBRT + ADT group. Thus, RP can provide superior cancer control with clear cost advantage for older men with high-risk disease. In terms of value proposition, our results support RP as preferred treatment option, compared to EBRT + ADT and EBRT + BT ± ADT for high-risk prostate cancer patients. PMID: 31285113 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
This article summarizes highlights from the 5 articles published in this issue of Seminars on the current state of radiation treatment and areas of continued development. PMID: 31280984 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Radiation Therapy | Research